<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103152</url>
  </required_header>
  <id_info>
    <org_study_id>isrctn91422391</org_study_id>
    <nct_id>NCT03103152</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression</brief_title>
  <acronym>PROVENT</acronym>
  <official_title>PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barts and the London School of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the acceptability and feasibility of recruitment to a randomised
      chemoprevention study of standard (300mg) or low dose (100mg) aspirin vs. placebo and/or
      Vitamin D3 vs. placebo in patients enrolled on an Active Surveillance programme for prostate
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PROVENT study is a randomised, double blind, placebo controlled feasibility study to
      examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease
      progression in men on Active Surveillance for prostate cancer

      The main outcome measure of the trial is the rate of patient recruitment to a randomised
      chemoprevention study in men enrolled on an Active Surveillance programme for prostate cancer

      Secondary outcomes include the response to treatment as determined by serial multi-parametric
      magnetic resonance imaging (MRI) of the prostate, biochemical disease progression and
      histological disease progression after 12 months of therapy and finally toxicity and/or
      allergy to both aspirin and Vitamin D3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patient recruitment to a randomised chemoprevention study in men enrolled on an Active Surveillance programme for prostate cancer. Number accrued per month.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment as determined by serial multi-parametric magnetic resonance imaging (MRI) of the prostate. New lesion present or existing lesion + or - in size.</measure>
    <time_frame>3 years</time_frame>
    <description>Lesion on multi-parametric imaging where no MRI lesion at screening. An MRI scan shows a screening + or - in volume by &gt; 33%, or an upgrading of MRI stage of disease to ≥3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical disease progression. 50% increase in serum Prostate Specific Antigen at 12 months from baseline.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological disease progression. Increase in Gleason score or MCCL</measure>
    <time_frame>3 years</time_frame>
    <description>Histological disease progression will be defined as an increase in Gleason scores from: Gleason 3+3 to Gleason score 7 or higher Gleason 3+4 (score 7) to 4+3 (score 7) or Gleason 4+3 to a higher score
Or a 50% increase in maximum cancer core length (MCCL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and/or allergy to both aspirin and Vitamin D3; Symptoms of Aspirin or Vit D toxicity.</measure>
    <time_frame>3 years</time_frame>
    <description>Aspirin toxicity: Haemorrhagic stroke, anaphylaxis following administration, gastrointestinal bleeding requiring intervention (both medical and surgical)
Vitamin D3 toxicity: Hypercalcaemia, Anaphylaxis</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>High dose Aspirin &amp; Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin high dose (300mgs) daily &amp; Vitamin D 4,000 IU (0.1mg) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Aspirin , Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose aspirin (100mgs) daily &amp; Vitamin D 4,000 IU (0.1mg) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Aspirin, Vitamin D placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin placebo, Vitamin D placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Aspirin &amp; Vitamin D</intervention_name>
    <description>Aspirin 1 x 300mg tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>High dose Aspirin &amp; Vitamin D</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Aspirin, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 300mg tablet daily &amp; Vitamin D placebo (8 drops).</description>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Aspirin , Vitamin D</intervention_name>
    <description>Aspirin 1 x 100mg tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>Low dose Aspirin , Vitamin D</arm_group_label>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Aspirin, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 100mg tablet daily &amp; Vitamin D placebo 8 drops daily.</description>
    <arm_group_label>Low dose Aspirin, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Placebo, Vitamin D</intervention_name>
    <description>Aspirin 1 x 300mg placebo tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin placebo, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 100mg placebo tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <arm_group_label>Aspirin placebo, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin Placebo, Vitamin D</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male subjects aged 16 years or over with an estimated life expectancy of more than
             three years

          2. Willing and able to provide written informed consent

          3. Corrected serum calcium &lt;2.65mmol/l

          4. No previous treatment for prostate cancer (including surgery, hormone therapy,
             radiotherapy, cryotherapy)

          5. All subjects must have had Magnetic Resonance Imaging (MRI) of the prostate with
             targeted biopsy of any lesions identified

          6. Histologically confirmed prostate cancer* following prostate biopsy (including at
             least 10 cores of prostate tissue) in men opting for Active Surveillance as their
             primary cancer therapy.

               -  *PROVENT Prostate Cancer Criteria for Inclusion:

                    -  Gleason score 6 or 7

                    -  Clinical and radiological stage &lt;T3

                    -  Serum PSA ≤15.0 ng/ml

                    -  Less than 10mm of cancer in a single core

        Patients must have undergone a multi-parametric MRI deemed assessable by the local
        radiologist, and any lesions seen must have undergone targeted biopsy (transrectal or
        transperineal) within 12 months of study enrolment.

        Exclusion Criteria:

          1. Previously treated prostate cancer (including radiotherapy, hormone therapy,
             brachytherapy or surgery)

          2. Current enrolment in an investigational drug, device or other clinical research study
             or participation in such a study within 30 days of randomisation

          3. Current daily use of aspirin or NSAIDs; or daily dietary supplements/medication
             containing more than 400 IU (10 micrograms per day) Vitamin D3; or chronic use
             (defined as &gt; 6 months continuous daily use) of either aspirin or replacement Vitamin
             D3 within two years of study enrolment

          4. Current or previous use of 5-α reductase inhibitors such as finasteride or dutasteride

          5. Not willing to comply with the procedural requirements of this protocol including
             repeat prostate biopsies

          6. Known allergy/sensitivity to or intolerance of aspirin, other salicylates or NSAIDs
             e.g. ibuprofen/ naproxen

          7. Prior history of gastro-intestinal bleeding or ulceration, severe dyspepsia or
             inflammatory bowel disease

          8. Haemophilia or other bleeding diatheses

          9. Prior history of renal stone disease

         10. Chronic renal disease (≥stage 4)

         11. Known hypercalcaemia (corrected serum calcium &gt;2.65 mmol/l) or untreated
             hyperparathyroidism

         12. Any bowel condition that would make repeat transrectal biopsy hazardous or difficult
             to perform e.g. recto-urethral fistula, or prior bowel surgery such as
             abdomino-perineal resection.

         13. Any malignancy (other than non-melanoma skin cancer) that has not been in complete
             remission for five years

         14. Any serious co-existent medical condition that would make repeat prostate biopsy
             hazardous e.g. anti-coagulation requiring continuous administration

         15. Severe Asthma

         16. G6PD deficiency

         17. Pre-existing macular degeneration

         18. All contraindications to aspirin and Vitamin D3, including concomitant therapy with
             any medication that may interact with aspirin or Vitamin D3 (see section 4.10)

         19. Regular consumption of alcohol units greater than the recommended daily limit of 3-4
             units per day (men)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Powles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Cuzick, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Queen Mary London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Powles, MD</last_name>
    <phone>0207 882 8498</phone>
    <email>thomas.powles@bartshealth.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roseann Kealy, MSc</last_name>
    <phone>0207 882 3520</phone>
    <email>r.kealy@qmul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>London</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital UHCW NHS Trust</name>
      <address>
        <city>London</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kieran Jefferson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomews Hospital London, Bart's and the London school of Medicine</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Powles, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital London</name>
      <address>
        <city>London</city>
        <zip>NW1 2B</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Moore, MD</last_name>
      <email>caroline.moore@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Caroline Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Cathcart, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Homerton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jhumur Pati, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Active Surveillance</keyword>
  <keyword>Chemo-prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

